AI Engines For more Details: Perplexity Kagi Labs You
Treatment of Ovarian Cancer: Altretamine, also known as hexamethylmelamine, is used as a second-line or salvage therapy for the treatment of advanced ovarian cancer. It is typically administered orally in capsule form.
Alkylating Agent: Altretamine is classified as an alkylating agent, which means it interferes with the DNA of cancer cells, preventing their replication and growth. It is believed to exert its anticancer effects by forming cross-links with DNA strands, leading to DNA damage and ultimately cell death.
Indications: Altretamine is indicated for the treatment of ovarian cancer that has recurred or progressed after initial chemotherapy. It may be used alone or in combination with other chemotherapeutic agents, such as platinum-based drugs or taxanes, depending on the specific characteristics of the cancer and individual patient factors.
Response Rates: Altretamine has been shown to produce responses in a subset of patients with recurrent ovarian cancer, particularly those with platinum-resistant disease. However, response rates are typically lower compared to first-line chemotherapy regimens, and the duration of response may be limited.
Side Effects: Common side effects of altretamine may include gastrointestinal symptoms such as nausea, vomiting, diarrhea, or loss of appetite. These side effects are usually mild to moderate in severity and may be managed with supportive care measures such as antiemetic medications or dietary modifications.
Bone Marrow Suppression: Altretamine can cause bone marrow suppression, leading to decreased production of blood cells, including white blood cells, red blood cells, and platelets. This may increase the risk of infections, anemia, and bleeding, particularly with prolonged or high-dose therapy.
Neurotoxicity: Altretamine has been associated with neurotoxicity, including peripheral neuropathy (nerve damage) and central nervous system effects such as dizziness, confusion, or cognitive impairment. Patients should be monitored for signs and symptoms of neurotoxicity during treatment, and dose adjustments may be necessary to manage these side effects.
Hepatotoxicity: Altretamine may cause liver toxicity, manifested by elevated liver enzymes and, rarely, liver failure. Patients taking altretamine should undergo regular monitoring of liver function tests to detect and manage potential hepatotoxicity.
Renal Toxicity: Altretamine has been associated with renal toxicity, including decreased kidney function and impaired urine concentration. Adequate hydration and urine alkalinization may be recommended to minimize the risk of renal toxicity during treatment.
Teratogenicity: Altretamine is teratogenic and should not be used during pregnancy. Women of childbearing potential should use effective contraception during treatment and for a period of time after discontinuation of altretamine therapy.
Drug Interactions: Altretamine may interact with other medications, including other chemotherapeutic agents or drugs that affect liver function or renal excretion. Close monitoring and dose adjustments may be necessary when altretamine is used concomitantly with other medications.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Bacteroides uniformis | Reduces |
| species | Escherichia coli | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.3 | 0.1 | 2 |
| ADHD | 2 | 2 | |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.4 | 0.25 |
| Allergic Rhinitis (Hay Fever) | 2 | 0.9 | 1.22 |
| Allergies | 2.1 | 0.6 | 2.5 |
| Allergy to milk products | 0.6 | 1.3 | -1.17 |
| Alopecia (Hair Loss) | 0.5 | 0.5 | |
| Alzheimer's disease | 3.1 | 2.5 | 0.24 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.5 | 0.8 | 0.88 |
| Ankylosing spondylitis | 1.9 | 0.7 | 1.71 |
| Anorexia Nervosa | 0.7 | 1.4 | -1 |
| Antiphospholipid syndrome (APS) | 1 | 1 | |
| Asthma | 2.1 | 1.1 | 0.91 |
| Atherosclerosis | 1.2 | 1.5 | -0.25 |
| Atrial fibrillation | 1.3 | 1.3 | 0 |
| Autism | 3.3 | 3.8 | -0.15 |
| Autoimmune Disease | 0.9 | 0.5 | 0.8 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.1 | 1.1 | |
| Bipolar Disorder | 1.3 | 0.5 | 1.6 |
| Brain Trauma | 0.3 | 0.8 | -1.67 |
| Breast Cancer | 0.4 | 0.4 | |
| Cancer (General) | 0.3 | 0.3 | |
| Carcinoma | 2 | 0.7 | 1.86 |
| Celiac Disease | 1.9 | 0.7 | 1.71 |
| Cerebral Palsy | 0.6 | 0.8 | -0.33 |
| Chronic Fatigue Syndrome | 1.7 | 1.8 | -0.06 |
| Chronic Kidney Disease | 1.5 | 0.7 | 1.14 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.3 | 1.1 | 0.18 |
| Chronic Urticaria (Hives) | 1.2 | 0.3 | 3 |
| Coagulation / Micro clot triggering bacteria | 1.6 | 0.8 | 1 |
| Cognitive Function | 1.6 | 0.8 | 1 |
| Colorectal Cancer | 4.6 | 1.4 | 2.29 |
| Constipation | 1.5 | 0.5 | 2 |
| Coronary artery disease | 1.3 | 1.1 | 0.18 |
| COVID-19 | 3.4 | 2.5 | 0.36 |
| Crohn's Disease | 4.5 | 1.8 | 1.5 |
| Cushing's Syndrome (hypercortisolism) | 0.6 | -0.6 | |
| cystic fibrosis | 0.9 | 0.8 | 0.13 |
| d-lactic acidosis (one form of brain fog) | 0.3 | 0.3 | |
| deep vein thrombosis | 1.8 | 1.1 | 0.64 |
| Denture Wearers Oral Shifts | 0.5 | 0.5 | |
| Depression | 4.6 | 2.9 | 0.59 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 1.3 | 0.7 | 0.86 |
| Endometriosis | 1.9 | 0.8 | 1.37 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
| Epilepsy | 2 | 1.1 | 0.82 |
| erectile dysfunction | 1.3 | 1.3 | |
| Fibromyalgia | 1.4 | 1.8 | -0.29 |
| Functional constipation / chronic idiopathic constipation | 2.9 | 1.7 | 0.71 |
| gallstone disease (gsd) | 1.7 | 0.8 | 1.13 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1 | 0.3 | 2.33 |
| Generalized anxiety disorder | 1.8 | 1.1 | 0.64 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.9 | 0.9 | |
| Graves' disease | 0.7 | 1.1 | -0.57 |
| Gulf War Syndrome | 0.3 | 0.3 | 0 |
| Halitosis | 1 | 0.3 | 2.33 |
| Hashimoto's thyroiditis | 1.6 | 0.4 | 3 |
| Heart Failure | 2.1 | 0.8 | 1.63 |
| hemorrhagic stroke | 0.7 | 0.7 | |
| Hidradenitis Suppurativa | 0.9 | 0.9 | |
| High Histamine/low DAO | 0.8 | 0.8 | |
| hypercholesterolemia (High Cholesterol) | 0.3 | 0.3 | |
| hyperglycemia | 1 | 0.7 | 0.43 |
| hypertension (High Blood Pressure | 2.2 | 1.4 | 0.57 |
| Hypothyroidism | 0.9 | 0.9 | |
| Hypoxia | 1.6 | 1.6 | |
| IgA nephropathy (IgAN) | 1.3 | 1.1 | 0.18 |
| Inflammatory Bowel Disease | 3.1 | 2.8 | 0.11 |
| Insomnia | 0.7 | 1.1 | -0.57 |
| Intelligence | 1.1 | 1.1 | |
| Intracranial aneurysms | 1 | 1 | |
| Irritable Bowel Syndrome | 2.6 | 2.3 | 0.13 |
| ischemic stroke | 1.3 | 1.4 | -0.08 |
| Liver Cirrhosis | 3.1 | 1.7 | 0.82 |
| Long COVID | 2.3 | 1.6 | 0.44 |
| Low bone mineral density | 0.5 | -0.5 | |
| Lung Cancer | 0.6 | 0.6 | |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1 | 1 | |
| ME/CFS with IBS | 0.3 | 0.3 | 0 |
| ME/CFS without IBS | 0.4 | 0.8 | -1 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.3 | 0.5 | -0.67 |
| Metabolic Syndrome | 3.1 | 2.9 | 0.07 |
| Mood Disorders | 4 | 2.6 | 0.54 |
| multiple chemical sensitivity [MCS] | 0.4 | 0.4 | |
| Multiple Sclerosis | 2.4 | 2.3 | 0.04 |
| Multiple system atrophy (MSA) | 0.3 | 0.3 | |
| myasthenia gravis | 0.9 | 0.5 | 0.8 |
| neuropathic pain | 1.3 | -1.3 | |
| Neuropathy (all types) | 0.3 | 1.9 | -5.33 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.3 | 0.8 | 1.87 |
| NonCeliac Gluten Sensitivity | 0.3 | 0.3 | 0 |
| Obesity | 3.4 | 2.4 | 0.42 |
| obsessive-compulsive disorder | 3 | 0.8 | 2.75 |
| Osteoarthritis | 1.7 | 0.6 | 1.83 |
| Osteoporosis | 1.4 | 0.6 | 1.33 |
| pancreatic cancer | 1.3 | 0.6 | 1.17 |
| Parkinson's Disease | 3 | 2.8 | 0.07 |
| Polycystic ovary syndrome | 4 | 1.1 | 2.64 |
| Premenstrual dysphoric disorder | 0.4 | -0.4 | |
| primary biliary cholangitis | 0.3 | 1.1 | -2.67 |
| Primary sclerosing cholangitis | 1.6 | 1 | 0.6 |
| Psoriasis | 0.9 | 1.7 | -0.89 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.3 | 1.4 | 0.64 |
| Rosacea | 0.1 | 0.5 | -4 |
| Schizophrenia | 2.4 | 1.3 | 0.85 |
| scoliosis | 0.3 | 0.3 | |
| Sjögren syndrome | 1.3 | 1.2 | 0.08 |
| Sleep Apnea | 0.3 | 0.8 | -1.67 |
| Slow gastric motility / Gastroparesis | 0.6 | 0.6 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.2 | 1.2 | |
| Stress / posttraumatic stress disorder | 1.8 | 1.3 | 0.38 |
| Systemic Lupus Erythematosus | 2.3 | 0.5 | 3.6 |
| Tic Disorder | 0.6 | 0.6 | |
| Tourette syndrome | 0.3 | 0.3 | 0 |
| Type 1 Diabetes | 2.2 | 1.4 | 0.57 |
| Type 2 Diabetes | 3.7 | 3.2 | 0.16 |
| Ulcerative colitis | 2.6 | 2.7 | -0.04 |
| Unhealthy Ageing | 1.8 | 1 | 0.8 |
| Vitiligo | 1.3 | 0.4 | 2.25 |
